menu search

Srpt investor notice: rosen, trusted investor counsel, encourages sarepta therapeutics, inc. investors to inquire about securities class action investigation – srpt

NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, continues investigating potential securities clai...

November 2, 2023, 1:37 am

Sarepta therapeutics stock halted after unveiling mixed results for its first gene therapy

Sarepta unveiled mixed results late Monday for a gene therapy that targets a muscle-wasting disease in boys. s...

October 30, 2023, 5:52 pm

Are gene therapy stocks the market's next big winners?

It's not often that you see a company whose main product comes with a price tag of over $2 million, but that's the case with biotechs BioMarin Pharmac...

September 25, 2023, 8:06 am

Sarepta therapeutics, inc. (srpt) q2 2023 earnings call transcript

Sarepta Therapeutics, Inc. (NASDAQ:SRPT ) Q2 2023 Earnings Conference Call August 2, 2023 4:30 PM ET Company Participants Francesca Nolan - IR Directo...

August 2, 2023, 9:57 pm

Sarepta therapeutics (srpt) reports q2 loss, misses revenue estimates

Sarepta Therapeutics (SRPT) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $1.89. This compares to...

August 2, 2023, 7:28 pm

Sarepta therapeutics (srpt) expected to beat earnings estimates: what to know ahead of q2 release

Sarepta Therapeutics (SRPT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared...

July 25, 2023, 11:39 am

Sarepta therapeutics: 'hold' amid market myopia

Sarepta reported a $516.8M loss in Q1 2023 but saw increased revenues ($253.5M) and holds $1.9B in assets. FDA's narrower approval for Elevidys impact...

July 13, 2023, 5:49 am

Sarepta therapeutics completes sale of priority review voucher for $102 million

Sarepta Therapeutics Inc. SRPT, -0.90% said Wednesday it has completed the sale of its Rare Pediatric Disease Priority Review Voucher for $102 million...

July 5, 2023, 8:37 am

Sarepta therapeutics gets fda nod, drops warning (or opportunity?)

On May 15, Sarepta Therapeutics Inc. NASDAQ: srpt learned that its treatment for Duchenne muscular dyst...

June 27, 2023, 9:01 am

Sarepta (srpt) gets fda's accelerated nod for dmd gene therapy

Following FDA???s approval, Sarepta's (SRPT) Elevidys becomes the first gene therapy for treating DMD....

June 23, 2023, 2:09 pm

Sarepta therapeutics downgraded at evercore isi after fda approval of gene therapy

Sarepta Therapeutics Inc. SRPT, -2.33%, which yesterday scored a win with U.S. Food and Drug Administration approval of the first gene therapy for chi...

June 23, 2023, 8:21 am

Sarepta therapeutics announces fda approval of first gene therapy to treat duchenne muscular dystrophy

Sarepta Therapeutics Inc (NASDAQ:SRPT) said the US Food and Drug Administration (FDA) has accelerated approval for ELEVIDYS, its first-of-a-kind gene ...

June 23, 2023, 8:09 am

Sarepta stock yo-yoes after winning highly anticipated gene therapy nod

Sarepta won approval Thursday for its highly anticipated Duchenne muscular dystrophy gene therapy. srpt ...

June 22, 2023, 3:05 pm

Sarepta (srpt) down 11% on fda extending dmd gene therapy review

The FDA extends the review period for Sarepta's (SRPT) BLA for DMD gene therapy by almost four weeks to Jun 22. The agency may limit the use of the th...

May 25, 2023, 3:17 pm

: sarepta says fda is working toward accelerated approval of its latest treatment for duchenne muscular dystrophy

Sarepta Therapeutics Inc. srpt said Wednesday that the U.S. Food and Drug Administration has indicated ...

May 24, 2023, 4:59 pm

Biotech stock drops on fda update

Sarepta Therapeutics Inc (NASDAQ:SRPT) is gaining some attention in the biotech realm today....

May 24, 2023, 10:53 am

Sarepta therapeutics dives on an unexpected hold-up for its gene therapy

The FDA pushed back its review of a highly anticipated gene therapy from Sarepta Therapeutics on Wednesday, prompting...

May 24, 2023, 9:04 am

Sarepta says fda is working toward accelerated approval of its latest treatment for duchenne muscular dystrophy

Sarepta Therapeutics Inc. SRPT, -1.45% said Wednesday that the U.S. Food and Drug Administration has indicated after talks with the company that it's ...

May 24, 2023, 8:15 am

Sarepta soars 31% as fda panel backs muscular dystrophy therapy

Sarepta Therapeutics Inc. NASDAQ: srpt jumped nearly 31% on May 15, after a Food and Drug Administratio...

May 16, 2023, 6:33 am

Sarepta's (srpt) dmd gene therapy gets endorsed by fda panel

The FDA's CTGTAC narrowly recommends granting accelerated approval to Sarepta's (SRPT) DMD gene therapy. A final decision from the agency is expected ...

May 15, 2023, 2:27 pm


Search within

Pages Search Results: